Parasites, Hosts and Diseases

"Sant Muangnoicharoen"

Original Articles

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand: Srivicha Krudsood, Noppadon Tangpukdee, Sant Muangnoicharoen, Vipa Thanachartwet, Nutthanej Luplertlop, Siripan Srivilairit, Polrat Wilairatana, Shigeyuki Kano, Pascal Ringwald, Sornchai Looareesuwan; Korean J Parasitol 2007;45(2):111-114.
Published online June 20, 2007; DOI: https://doi.org/10.3347/kjp.2007.45.2.111

Abstract
PDF

Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.

Citations

Citations to this article as recorded by

Drug resistance markers in Plasmodium vivax isolates from a Kanchanaburi province, Thailand between January to May 2023
Thanawat Sridapan, Paweesuda Rattanakoch, Kaewkanha Kijprasong, Suttipat Srisutham, Kristan Alexander Schneider
PLOS ONE.2024; 19(7): e0304337. CrossRef
Adapted Guidelines for Malaria Case Management in Sudan
Samah Elhassan, Sahar Khalid Mohamed, Khlood Fathi Hassan Alnaeem, Ahmed Abdulgadir Noureddin, Samah Kamaleldeen Bakrri Abass, Fadwa Mohamed Saad, Technical Advisory Committee
Sudan Journal of Medical Sciences.2024; 19(4): 531. CrossRef
Plasmodium knowlesi as a model system for characterising Plasmodium vivax drug resistance candidate genes
Lisa H. Verzier, Rachael Coyle, Shivani Singh, Theo Sanderson, Julian C. Rayner, Paulo Pimenta
PLOS Neglected Tropical Diseases.2019; 13(6): e0007470. CrossRef
Management of relapsingPlasmodium vivaxmalaria
Cindy S Chu, Nicholas J White
Expert Review of Anti-infective Therapy.2016; 14(10): 885. CrossRef
Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review
Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana
Annals of the Academy of Medicine, Singapore.2016; 45(7): 303. CrossRef
Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review
Benjamin J Visser, Rosanne W Wieten, Daniëlle Kroon, Ingeborg M Nagel, Sabine Bélard, Michèle van Vugt, Martin P Grobusch
Malaria Journal.2014;[Epub] CrossRef
Malaria: an update on current chemotherapy
Benjamin J Visser, Michèle van Vugt, Martin P Grobusch
Expert Opinion on Pharmacotherapy.2014; 15(15): 2219. CrossRef
Effectiveness of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax and P. falciparum Malaria in Young Children in Papua New Guinea
Nicolas Senn, Patricia Rarau, Doris Manong, Mary Salib, Peter Siba, John C. Reeder, Stephen J. Rogerson, Blaise Genton, Ivo Mueller
Clinical Infectious Diseases.2013; 56(10): 1413. CrossRef
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria
Nithya Gogtay, Sridharan Kannan, Urmila M Thatte, Piero L Olliaro, David Sinclair
Cochrane Database of Systematic Reviews.2013;[Epub] CrossRef
Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan
Tajeldin M Abdallah, Abdel Aziem A Ali, Mohammed Bakri, Gasim I Gasim, Imad R Musa, Ishag Adam
Malaria Journal.2012;[Epub] CrossRef
Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana
Daniel Eibach, Nicolas Ceron, Karanchand Krishnalall, Keith Carter, Guillaume Bonnot, Anne-Lise Bienvenu, Stéphane Picot
Malaria Journal.2012;[Epub] CrossRef
Coartem®: a decade of patient-centric malaria management
Kamal Hamed, Heiner Grueninger
Expert Review of Anti-infective Therapy.2012; 10(6): 645. CrossRef
Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia
Teferi Eshetu, Nasir Abdo, Kunuz H Bedru, Sintayehu Fekadu, Andreas Wieser, Michael Pritsch, Thomas Löscher, Nicole Berens-Riha
Malaria Journal.2012;[Epub] CrossRef
Primaquine in vivax malaria: an update and review on management issues
Deepika Fernando, Chaturaka Rodrigo, Senaka Rajapakse
Malaria Journal.2011;[Epub] CrossRef
Plasmodium vivax treatments
Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein
Current Opinion in Infectious Diseases.2011; 24(6): 578. CrossRef
Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial
Yi Poravuth, Duong Socheat, Ronnatrai Rueangweerayut, Chirapong Uthaisin, Aung Pyae Phyo, Neena Valecha, B. H. Krishnamoorthy Rao, Emiliana Tjitra, Asep Purnama, Isabelle Borghini-Fuhrer, Stephan Duparc, Chang-Sik Shin, Lawrence Fleckenstein, Lorenz von S
PLoS ONE.2011; 6(1): e14501. CrossRef
The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
Quique Bassat, David Joseph Diemert
PLoS Neglected Tropical Diseases.2011; 5(12): e1325. CrossRef
Confirmed Vivax Resistance to Chloroquine and Effectiveness of Artemether-Lumefantrine for the Treatment of Vivax Malaria in Ethiopia
Ambachew M. Yohannes, Pascal Ringwald, Awash Teklehaimanot, Yngve Bergqvist
The American Journal of Tropical Medicine and Hygiene.2011; 84(1): 137. CrossRef
Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries
Cho Naing, Kyan Aung, Daw-Khin Win, Mak Joon Wah
Transactions of the Royal Society of Tropical Medicine and Hygiene.2010; 104(11): 695. CrossRef
Artemisinin combination therapy for vivax malaria
Nicholas M Douglas, Nicholas M Anstey, Brian J Angus, Francois Nosten, Ric N Price
The Lancet Infectious Diseases.2010; 10(6): 405. CrossRef
The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies
J. D. Maguire, J. K. Baird
Annals of Tropical Medicine & Parasitology.2010; 104(4): 283. CrossRef
Application of mobile-technology for disease and treatment monitoring of malaria in the "Better Border Healthcare Programme"
Pongthep Meankaew, Jaranit Kaewkungwal, Amnat Khamsiriwatchara, Podjadeach Khunthong, Pratap Singhasivanon, Wichai Satimai
Malaria Journal.2010;[Epub] CrossRef
Resistance to Therapies for Infection byPlasmodium vivax
J. Kevin Baird
Clinical Microbiology Reviews.2009; 22(3): 508. CrossRef

8,406 View
100 Download
Crossref

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand: Srivicha Krudsood, Polrat Wilairatana, Noppadon Tangpukdee, Kobsiri Chalermrut, Siripun Srivilairit, Vipa Thanachartwet, Sant Muangnoicharoen, Natthanej Luplertlop, Gary M. Brittenham, Sornchai Looareesuwan; Korean J Parasitol 2006;44(3):221-228.
Published online September 20, 2006; DOI: https://doi.org/10.3347/kjp.2006.44.3.221

Abstract
PDF

We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.

Citations

Citations to this article as recorded by

Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency
Huaie Liu, Weilin Zeng, Pallavi Malla, Chengqi Wang, Seetha Lakshmi, Kami Kim, Lynette Menezes, Zhaoqing Yang, Liwang Cui
Infection.2023; 51(1): 213. CrossRef
Plasmodium cynomolgi in humans: current knowledge and future directions of an emerging zoonotic malaria parasite
Loick P. Kojom Foko, Amit Kumar, Joseph Hawadak, Vineeta Singh
Infection.2023; 51(3): 623. CrossRef
The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients
Ziyu Zhang, Qinhui Li, Xiaoyan Shen, Lankai Liao, Xia Wang, Min Song, Xi Zheng, Yulian Zhu, Yong Yang
Frontiers in Pharmacology.2022;[Epub] CrossRef
G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
Germana Bancone, Cindy S. Chu
Frontiers in Pharmacology.2021;[Epub] CrossRef
Targeting Gametocytes of the Malaria Parasite Plasmodium falciparum in a Functional Genomics Era: Next Steps
Jyotsna Chawla, Jenna Oberstaller, John H. Adams
Pathogens.2021; 10(3): 346. CrossRef
Recent Advances in Transmission-Blocking Drugs for Malaria Elimination
Ishan Wadi, Mahendra Nath, Anupkumar R Anvikar, Pargat Singh, Abhinav Sinha
Future Medicinal Chemistry.2019; 11(23): 3047. CrossRef
G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients
Sara Avalos, Rosa E. Mejia, Engels Banegas, Cesar Salinas, Lester Gutierrez, Marcela Fajardo, Suzeth Galo, Alejandra Pinto, Angel Mejia, Gustavo Fontecha
Malaria Journal.2018;[Epub] CrossRef
A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications
Hazem Elewa, Kyle John Wilby
European Journal of Drug Metabolism and Pharmacokinetics.2017; 42(5): 745. CrossRef
Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies
Olalekan A. Uthman, Patricia M. Graves, Rachel Saunders, Hellen Gelband, Marty Richardson, Paul Garner
Malaria Journal.2017;[Epub] CrossRef
Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond
Ken Ing Cherng Ong, Hodaka Kosugi, Sophea Thoeun, Hitomi Araki, Moe Moe Thandar, Moritoshi Iwagami, Bouasy Hongvanthong, Paul T Brey, Shigeyuki Kano, Masamine Jimba
BMJ Global Health.2017; 2(3): e000415. CrossRef
Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review
Hariharan Subramony, Noppadon Tangpukdee, Srivicha Krudsood, Kittiyod Poovorawan, Sant Muangnoicharoen, Polrat Wilairatana
Annals of the Academy of Medicine, Singapore.2016; 45(7): 303. CrossRef
Enantioselective Pharmacokinetics of Primaquine in Healthy Human Volunteers
Babu L Tekwani, Bharathi Avula, Rajnish Sahu, Narayan D Chaurasiya, Shabana I Khan, Surendra Jain, Pius S Fasinu, H.M.T. Bandara Herath, Donald Stanford, N.P. Dhammika Nanayakkara, James D McChesney, Travis W Yates, Mahmoud A ElSohly, Ikhlas A Khan, Larry
Drug Metabolism and Disposition.2015; 43(4): 571. CrossRef
“Recycling” Classical Drugs for Malaria
Cátia Teixeira, Nuno Vale, Bianca Pérez, Ana Gomes, José R. B. Gomes, Paula Gomes
Chemical Reviews.2014; 114(22): 11164. CrossRef
KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro
Anne-Marie Zeeman, Sandra M. van Amsterdam, Case W. McNamara, Annemarie Voorberg-van der Wel, Els J. Klooster, Alexander van den Berg, Edmond J. Remarque, David M. Plouffe, Geert-Jan van Gemert, Adrian Luty, Robert Sauerwein, Kerstin Gagaring, Rachel Borb
Antimicrobial Agents and Chemotherapy.2014; 58(3): 1586. CrossRef
Novel approaches in antimalarial drug discovery
Jana Held, Andrea Kreidenweiss, Benjamin Mordmüller
Expert Opinion on Drug Discovery.2013; 8(11): 1325. CrossRef
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran
Cochrane Database of Systematic Reviews.2013;[Epub] CrossRef
Effects of Antimalarial Molecules on the Gametocyte Stage of Plasmodium falciparum: The Debate
Odile Dechy-Cabaret, Françoise Benoit-Vical
Journal of Medicinal Chemistry.2012; 55(23): 10328. CrossRef
Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal
Tiago Rodrigues, Miguel Prudêncio, Rui Moreira, Maria M. Mota, Francisca Lopes
Journal of Medicinal Chemistry.2012; 55(3): 995. CrossRef
PharmGKB summary
Ellen M. McDonagh, Caroline F. Thorn, José M. Bautista, Ilan Youngster, Russ B. Altman, Teri E. Klein
Pharmacogenetics and Genomics.2012; 22(3): 219. CrossRef
New approaches in antimalarial drug discovery and development: a review
Anna Caroline C Aguiar, Eliana MM da Rocha, Nicolli B de Souza, Tanos CC França, Antoniana U Krettli
Memórias do Instituto Oswaldo Cruz.2012; 107(7): 831. CrossRef
Plasmodium vivax treatments
Ric N. Price, Nicholas M. Douglas, Nicholas M. Anstey, Lorenz von Seidlein
Current Opinion in Infectious Diseases.2011; 24(6): 578. CrossRef
Feeding the Antimalarial Pipeline
Martin Schlitzer, Regina Ortmann
ChemMedChem.2010; 5(11): 1837. CrossRef
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination
Timothy N.C. Wells, Jeremy N. Burrows, J. Kevin Baird
Trends in Parasitology.2010; 26(3): 145. CrossRef
Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials
Anthony E. Kiszewski
Pharmaceuticals.2010; 4(1): 44. CrossRef
Medications and Glucose-6-Phosphate Dehydrogenase Deficiency
Ilan Youngster, Lidia Arcavi, Renata Schechmaster, Yulia Akayzen, Hen Popliski, Janna Shimonov, Svetlana Beig, Matitiahu Berkovitch
Drug Safety.2010; 33(9): 713. CrossRef
A pre-emptive strike against malaria's stealthy hepatic forms
Dominique Mazier, Laurent Rénia, Georges Snounou
Nature Reviews Drug Discovery.2009; 8(11): 854. CrossRef
Resistance to Therapies for Infection byPlasmodium vivax
J. Kevin Baird
Clinical Microbiology Reviews.2009; 22(3): 508. CrossRef
8-Aminoquinolines: future role as antiprotozoal drugs
Babu L Tekwani, Larry A Walker
Current Opinion in Infectious Diseases.2006; 19(6): 623. CrossRef